Ajinomoto enters US medical foods market with Cambrooke Therapeutics acquisition

d007b1c1-fd67-4634-8a60-b76bdb1f45dearticleimage.jpg

09 Nov 2017 --- Ajinomoto Co. Inc has acquired an equity position in US medical foods company Cambrooke Therapeutics, Inc through Ajinomoto North America, Inc. (Ajina) for approximately US$64 million and made it a wholly owned subsidiary. Founded in 2000, Cambrooke develops and manufactures medical foods for patients with amino acid metabolism disorders and other customers. 

It also makes products such as medical foods for patients with intractable epilepsy and low-protein foods for patients with kidney and liver diseases, as well as rolling out its product lineup outside the US in Europe and elsewhere. 

The medical nutrition innovator says it uses original ingredients to develop products that are superior to competing products in taste, digestibility and has achieved a high rate of growth exceeding 20 percent annually for the past three years.

The market for medical foods in the US is the largest in the world at US$1,750 million in 2016, with a solid compound annual growth rate (CAGR) of approximately 10 percent.

The category of foods for patients with metabolic disorders accounts for about 40 percent of this market at US$660 million and is growing at an annual rate of 10 percent, estimates Ajinomoto. 

Patients with metabolic disorders are unable to ingest regular foods and must eat only specified medical foods on a daily basis, but the palatability and lack of variety of these foods has been a major issue.

For years, Ajinomoto Co. has sold amino acids into the medical foods market as ingredients. With this acquisition, the company will make a full-scale entry into that market. 

It says that by applying its scientific knowledge of amino acids’ nutritional and physiological functions, “deliciousness technologies” and food application technologies to Cambrooke’s operations, it will offer enhanced foods to patients with metabolic disorders. 

Increase market share
In addition, by adding to the disease areas covered and using its sales channels outside Japan to strengthen Cambrooke’s overseas rollout, Ajinomoto Co. aims to expand its share of the global market for medical foods for patients with amino acid metabolism disorders to 20 percent, with sales of approximately US$90 million by 2027.

Moreover, by incorporating Cambrooke’s knowledge of the medical foods business into Ajinomoto Co.’s food-related businesses in Japan and overseas, including processed foods, healthcare foods and supplements, Ajinomoto Co. intends to expand its lineup of high-value-added health and nutrition-related products.

Ajinomoto Co. has been conducting Food Products and AminoScience businesses centered on proprietary leading-edge bioscience and fine chemical technologies that it has cultivated over many years through research based on amino acids. 

This closely follows Ajinomoto’s completion of procedures for the acquisition of all shares of Labeyrie Traiteur Surgelés S.A.S. (LTS) through its consolidate subsidiary Ajinomoto Foods Europe S.A.S. in accordance with details announced on July 20, 2017.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Zero proof that probiotics can ease your anxiety, research reveals

21 Jun 2018 --- Those hoping to alleviate their anxiety with the use of probiotics should probably put down that yogurt spoon or supplement bottle and call a professional instead. This is according to researchers from the University of Kansas who reviewed available research, finding evidence that probiotics can reduce anxiety in rodents, but not in humans. The researchers reviewed data from 22 preclinical studies involving 743 animals and 14 clinical studies of 1,527 individuals, and found that probiotics did “not significantly reduce symptoms of anxiety in humans and did not differentially affect clinical and healthy human samples.”

Business News

Probiotic expansion: General Mills leads investment in GoodBelly parent

21 Jun 2018 --- General Mills' venture arm, 301 Inc., is leading a US$12 million round in funding in NextFoods the parent company of GoodBelly Probiotics. Additional capital is coming from existing investors, including Emil Capital Partners. NextFoods was founded in 2007 by Todd Beckman and Steve Demos, who founded WhiteWave Foods, the owner of Silk plant-based milk.

Nutrition & Health News

Infant nutrition (part 2): Innovations in feeding the first 1,000 days

20 Jun 2018 --- Although breast milk is the most nutritious and advisable way to feed an infant for the first six months of life, as advised by the World Health Organization, there are situations that necessitate good quality breast milk substitutes. Part one of this two-part series on infant nutrition focused on the R&D challenges facing formula manufacturers. This second section focuses on the innovations in the ever-evolving market of Breast Milk Substitutes (BMS), as shared by a range of suppliers, as well as a look at the upcoming trends.

Nutrition & Health News

In your blood: Blood sample could uncover whether a person is following their prescribed diet

20 Jun 2018 --- Clinical trials of diets and their health impacts are often plagued by participants’ poor adherence to assigned diets, making it difficult to detect the true effects of those diets. An analysis of small molecules called “metabolites” in a blood sample may be used to determine whether a person is following a prescribed diet, scientists at Johns Hopkins Bloomberg School of Public Health have shown. The new approach, described in a paper in the American Journal of Clinical Nutrition, could provide an objective and relatively easy-to-obtain measure of dietary adherence, potentially greatly reducing the uncertainty of dietary intake estimates.

Packaging & Technology News

Confusing cereals? UK consumer group calls for clearer labeling post Brexit

20 Jun 2018 --- A Which? investigation into the sugar content of “adult” breakfast cereals has unveiled high sugar levels and ignited calls for the UK Government to make traffic light labeling mandatory after Brexit, when EU laws are transferred to British law.

More Articles
URL : http://www.nutritioninsight.com:80/news/ajinomoto-enters-us-medical-foods-market-with-cambrooke-therapeutics-acquisition.html